Association of PET vascular activity score with Takayasu's arteritis angiographic progression.

IF 8.6 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Sifan Wu, Bing Wu, Lingying Ma, Mengdi Li, Xianting Sun, Shuhui Zhang, Hongcheng Shi, Lindi Jiang
{"title":"Association of PET vascular activity score with Takayasu's arteritis angiographic progression.","authors":"Sifan Wu, Bing Wu, Lingying Ma, Mengdi Li, Xianting Sun, Shuhui Zhang, Hongcheng Shi, Lindi Jiang","doi":"10.1007/s00259-025-07348-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Arterial wall Fluorodeoxyglucose (FDG) uptake can reflect vascular inflammation in Takayasu's arteritis (TAK); however, its association with vascular prognosis remains unclear. This study assessed the predictive efficacy of the PET vascular activity score (PETVAS) for vascular prognosis and whether FDG uptake in specific arterial territories was associated with angiographic progression in TAK.</p><p><strong>Methods: </strong>Patients with TAK from a prospective observational cohort who underwent <sup>18</sup>F-FDG PET/CT and serological tests at baseline were included. Magnetic Resonance Angiography and/or Contrast-Enhanced Ultrasound were conducted at baseline and every six months during follow-up. The PETVAS was calculated. New/aggravated lesions were considered as angiographic progression.</p><p><strong>Results: </strong>The imaging evaluation included 1,353 arterial territories from 123 patients. The baseline PETVAS was positively correlated with Erythrocyte Sedimentation Rate (ESR), serum IL-6, and Platelet. Angiographic progression was noted in 45 patients (36.6%) with 72 territories (5.3%) during 30 (18-72) months of follow-up. Of these, 19 (42.2%) had baseline PETVAS > 15, including 84.2% (16/19) naïve cases and 78.9% (15/19) with ESR ≥ 30 mm/h. Multivariate Cox proportional hazards regression analysis adjusted for age and sex showed baseline PETVAS > 15 (HR 1.93; 95% CI, 1.01-3.68; p = 0.04) an independent predictor of angiographic progression.</p><p><strong>Conclusion: </strong>Baseline PETVAS > 15 was an independent predictor of angiographic progression in TAK. Baseline FDG uptake in specific arterial territories did not correlate with vascular progression. Our study provides a feasible PET/CT-based predictive marker for vascular progression in TAK and underscores the importance of regular imaging follow-up to monitor disease outcomes.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6000,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-025-07348-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Arterial wall Fluorodeoxyglucose (FDG) uptake can reflect vascular inflammation in Takayasu's arteritis (TAK); however, its association with vascular prognosis remains unclear. This study assessed the predictive efficacy of the PET vascular activity score (PETVAS) for vascular prognosis and whether FDG uptake in specific arterial territories was associated with angiographic progression in TAK.

Methods: Patients with TAK from a prospective observational cohort who underwent 18F-FDG PET/CT and serological tests at baseline were included. Magnetic Resonance Angiography and/or Contrast-Enhanced Ultrasound were conducted at baseline and every six months during follow-up. The PETVAS was calculated. New/aggravated lesions were considered as angiographic progression.

Results: The imaging evaluation included 1,353 arterial territories from 123 patients. The baseline PETVAS was positively correlated with Erythrocyte Sedimentation Rate (ESR), serum IL-6, and Platelet. Angiographic progression was noted in 45 patients (36.6%) with 72 territories (5.3%) during 30 (18-72) months of follow-up. Of these, 19 (42.2%) had baseline PETVAS > 15, including 84.2% (16/19) naïve cases and 78.9% (15/19) with ESR ≥ 30 mm/h. Multivariate Cox proportional hazards regression analysis adjusted for age and sex showed baseline PETVAS > 15 (HR 1.93; 95% CI, 1.01-3.68; p = 0.04) an independent predictor of angiographic progression.

Conclusion: Baseline PETVAS > 15 was an independent predictor of angiographic progression in TAK. Baseline FDG uptake in specific arterial territories did not correlate with vascular progression. Our study provides a feasible PET/CT-based predictive marker for vascular progression in TAK and underscores the importance of regular imaging follow-up to monitor disease outcomes.

Clinical trial number: Not applicable.

PET血管活动评分与高松动脉炎血管造影进展的关系。
目的:动脉壁氟脱氧葡萄糖(FDG)摄取可反映高松动脉炎(Takayasu’s arteritis, TAK)的血管炎症;然而,其与血管预后的关系尚不清楚。本研究评估了PET血管活动评分(PETVAS)对血管预后的预测效果,以及特定动脉区域的FDG摄取是否与TAK的血管造影进展有关。方法:前瞻性观察队列中的TAK患者在基线时接受了18F-FDG PET/CT和血清学检查。在基线和随访期间每6个月进行一次磁共振血管造影和/或超声造影。计算PETVAS。新的/加重的病变被认为是血管造影进展。结果:影像学评估包括123例患者的1,353个动脉区域。基线PETVAS与红细胞沉降率(ESR)、血清IL-6和血小板呈正相关。在30(18-72)个月的随访中,有45例患者(36.6%)、72个地区(5.3%)出现血管造影进展。其中,19例(42.2%)基线PETVAS为bb15,其中84.2% (16/19)naïve病例和78.9% (15/19)ESR≥30 mm/h。经年龄和性别校正的多因素Cox比例风险回归分析显示,基线PETVAS 1.15 (HR 1.93;95% ci, 1.01-3.68;P = 0.04)是血管造影进展的独立预测因子。结论:基线PETVAS bbb15是TAK血管造影进展的独立预测因子。特定动脉区域的FDG基线摄取与血管进展无关。我们的研究为TAK的血管进展提供了一个可行的基于PET/ ct的预测指标,并强调了定期影像学随访监测疾病结局的重要性。临床试验号:不适用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.60
自引率
9.90%
发文量
392
审稿时长
3 months
期刊介绍: The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信